METOJECT SUBCUTANEOUS 12.5 MG / 0.25 ML
METHOTREXATE (METHOTREXATE SODIUM) : 12.5 MG / 0.25 ML · DIN 02454750 · MEDEXUS PHARMACEUTICALS INC.
Health Canada status: MARKETED
What is METOJECT SUBCUTANEOUS?
METOJECT SUBCUTANEOUS 12.5 MG / 0.25 ML contains METHOTREXATE (METHOTREXATE SODIUM) : 12.5 MG / 0.25 ML. It is listed in the Health Canada Drug Product Database under DIN 02454750, held by MEDEXUS PHARMACEUTICALS INC., supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 16-Sep-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is METOJECT SUBCUTANEOUS used for?
METOJECT SUBCUTANEOUS (methotrexate injection) is indicated as a Disease Modifying Antirheumatic Drug (DMARD) in the following diseases where standard therapeutic interventions fail: Severe disabling psoriasis/psoriatic arthritis, Severe disabling rheumatoid arthritis (RA). In the treatment of psoriasis, METOJECT SUBCUTANEOUS should be restricted to severe recalcitrant, disabling psoriasis, which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established after dermatologic consultation. METOJECT SUBCUTANEOUS is not indicated for the treatment of neoplastic diseases.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02454750 |
|---|---|
| Brand name | METOJECT SUBCUTANEOUS |
| Generic / active ingredient | METHOTREXATE (METHOTREXATE SODIUM) : 12.5 MG / 0.25 ML |
| Manufacturer | MEDEXUS PHARMACEUTICALS INC. |
| Strength | 12.5 MG / 0.25 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L04AX03 METHOTREXATE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Sep-2019 |
| Original market date | 2019-09-16 00:00:00 |
How is it stored and handled?
null
How is it supplied?
1, 4, or 12 single-use pre-filled syringes with embedded injection needles (type 27 G, ½ inch, made from stainless steel), packed in blisters
Is METHOTREXATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by ACCORD HEALTHCARE INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L04AX03 METHOTREXATE. 29 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-METHOTREXATE | 2.5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02524023 |
| METHOFILL SELF-DOSE INJECTOR | 10 MG / 0.2 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530775 |
| METHOFILL SELF-DOSE INJECTOR | 12.5 MG / 0.25 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530783 |
| METHOFILL SELF-DOSE INJECTOR | 15 MG / 0.3 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530791 |
| METHOFILL SELF-DOSE INJECTOR | 17.5 MG / 0.35 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530805 |
| METHOFILL SELF-DOSE INJECTOR | 20 MG / 0.4 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530813 |
| METHOFILL SELF-DOSE INJECTOR | 22.5 MG / 0.45 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530848 |
| METHOFILL SELF-DOSE INJECTOR | 25 MG / 0.5 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02530856 |
| METHOTREXATE SUBCUTANEOUS | 10 MG / 0.2 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02491281 |
| METHOTREXATE SUBCUTANEOUS | 12.5 MG / 0.25 ML | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | DIN 02491303 |
Who else supplies METHOTREXATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHOTREXATE appears in 251 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.